24/09/2025 Ignacio Muñoz-Sanjuan, neuroscientist and founder of the non-profit Factor-H, has expressed optimism that an experimental gene therapy for Huntington’s disease, developed by uniQure and called AMT-130, could receive regulatory approval in the first half of 2026, in what is a very significant milestone for patients and families affected by…